3-D printed wrist splints for arthritis sufferers

Date:

July 1, 2014

Source:

University of Loughborough

Summary:

A computer software concept has been developed that will enable clinicians with no experience in Computer Aided Design (CAD) to design and make custom-made 3D printed wrist splints for rheumatoid arthritis sufferers. The 3D printed splints are not only more comfortable and attractive but potentially cheaper than the current ones that are 'ugly, bulky, and can make a patients arm sweat'.

A Loughborough University lecturer has developed a computer software concept that will enable clinicians with no experience in Computer Aided Design (CAD) to design and make custom-made 3D printed wrist splints for rheumatoid arthritis sufferers.

Dr Abby Paterson, from the Design School, said: "I wanted to give clinicians the ability to make splints they have not been able to make before. They can improve the aesthetics, the fit, and integrate extra bits of functionality they couldn't do before as a result of our Additive Manufacturing facilities here at Loughborough University. Thanks to our Objet Connex machine, we can integrate multiple materials in a single splint such as rubber-like integral hinges or cushioning features but, more importantly, the specialised software prototype we've developed will enable clinicians to design these splints for their patients."

The 3D printed splints are not only more comfortable and attractive but potentially cheaper than the current ones that are 'ugly, bulky, and can make a patients arm sweat'. As a result patients do not use them as often as they should.

The splints, which provide joint protection, rest, and promote pain relief,could be a major boost for sufferers of rheumatoid arthritis, the second most common type of arthritis in the UK which affects more than 400,000 people.

The splints are made by scanning a patient's arm in the 'appropriate position'. A 3D model splint is then designed based on the scan to generate a computer model.

The 3D printer can then produce as many splints as are needed at the touch of a button. They can be any colour, feature multiple materials, have a lattice design to aid ventilation and any type of fastening the patient requires.

The 3D CAD software prototype was shown to certified splinting practitioners, such as occupational therapists and physiotherapists.

Dr Paterson said: "The practitioners were very excited by new, novel ideas to expand the possibilities available to them, such as integrated rubber borders for increased comfort."

The 3D CAD software prototype is the product of Dr Paterson's PhD and development ‎work is still needed on the software and materials. ‎

Dr Paterson was supervised during her PhD by Dr Richard Bibb and Dr Ian Campbell. Dr Bibb came up with the idea for bespoke wrist splints in the late 1990's.

Dr Bibb and Dr Paterson are currently pursuing opportunities to perform a 'thorough cost analysis' of providing the service.

Dr Bibb says the 3D splints could be cheaper than the current ones because the design and manufacture stages have been separated. He believes they will be cost-effective for the NHS while the 'sky's the limit' in the private sector.

Dr Bibb, Reader in Medical Applications of Design in the Design School, said: "We are in the development phase. The research has proved that this is desirable and the clinicians want it. We know there's lots of potential."

---

Story Source:

The above story is based on materials provided by University of Loughborough.Note: Materials may be edited for content and length.

Read More

Noninvasive brain control: New light-sensitive protein enables simpler, more powerful optogenetics

Date:

June 29, 2014

Source:

Massachusetts Institute of Technology

Summary:

Engineers have now developed the first light-sensitive molecule that enables neurons to be silenced noninvasively, using a light source outside the skull. This noninvasive approach could pave the way to using optogenetics in human patients to treat epilepsy and other neurological disorders.

Optogenetics, a technology that allows scientists to control brain activity by shining light on neurons, relies on light-sensitive proteins that can suppress or stimulate electrical signals within cells. This technique requires a light source to be implanted in the brain, where it can reach the cells to be controlled.

MIT engineers have now developed the first light-sensitive molecule that enables neurons to be silenced noninvasively, using a light source outside the skull. This makes it possible to do long-term studies without an implanted light source. The protein, known as Jaws, also allows a larger volume of tissue to be influenced at once.

This noninvasive approach could pave the way to using optogenetics in human patients to treat epilepsy and other neurological disorders, the researchers say, although much more testing and development is needed. Led by Ed Boyden, an associate professor of biological engineering and brain and cognitive sciences at MIT, the researchers described the protein in the June 29 issue of Nature Neuroscience.

Optogenetics, a technique developed over the past 15 years, has become a common laboratory tool for shutting off or stimulating specific types of neurons in the brain, allowing neuroscientists to learn much more about their functions.

The neurons to be studied must be genetically engineered to produce light-sensitive proteins known as opsins, which are channels or pumps that influence electrical activity by controlling the flow of ions in or out of cells. Researchers then insert a light source, such as an optical fiber, into the brain to control the selected neurons.

Such implants can be difficult to insert, however, and can be incompatible with many kinds of experiments, such as studies of development, during which the brain changes size, or of neurodegenerative disorders, during which the implant can interact with brain physiology. In addition, it is difficult to perform long-term studies of chronic diseases with these implants.

Mining nature's diversity

To find a better alternative, Boyden, graduate student Amy Chuong, and colleagues turned to the natural world. Many microbes and other organisms use opsins to detect light and react to their environment. Most of the natural opsins now used for optogenetics respond best to blue or green light.

Boyden's team had previously identified two light-sensitive chloride ion pumps that respond to red light, which can penetrate deeper into living tissue. However, these molecules, found in the bacteria Haloarcula marismortui and Haloarcula vallismortis, did not induce a strong enough photocurrent -- an electric current in response to light -- to be useful in controlling neuron activity.

Chuong set out to improve the photocurrent by looking for relatives of these proteins and testing their electrical activity. She then engineered one of these relatives by making many different mutants. The result of this screen, Jaws, retained its red-light sensitivity but had a much stronger photocurrent -- enough to shut down neural activity.

"This exemplifies how the genomic diversity of the natural world can yield powerful reagents that can be of use in biology and neuroscience," says Boyden, who is a member of MIT's Media Lab and the McGovern Institute for Brain Research.

Using this opsin, the researchers were able to shut down neuronal activity in the mouse brain with a light source outside the animal's head. The suppression occurred as deep as 3 millimeters in the brain, and was just as effective as that of existing silencers that rely on other colors of light delivered via conventional invasive illumination.

A key advantage to this opsin is that it could enable optogenetic studies of animals with larger brains, says Garret Stuber, an assistant professor of psychiatry and cell biology and physiology at the University of North Carolina at Chapel Hill.

"In animals with larger brains, people have had difficulty getting behavior effects with optogenetics, and one possible reason is that not enough of the tissue is being inhibited," he says. "This could potentially alleviate that."

Restoring vision

Working with researchers at the Friedrich Miescher Institute for Biomedical Research in Switzerland, the MIT team also tested Jaws's ability to restore the light sensitivity of retinal cells called cones. In people with a disease called retinitis pigmentosa, cones slowly atrophy, eventually causing blindness.

Friedrich Miescher Institute scientists Botond Roska and Volker Busskamp have previously shown that some vision can be restored in mice by engineering those cone cells to express light-sensitive proteins. In the new paper, Roska and Busskamp tested the Jaws protein in the mouse retina and found that it more closely resembled the eye's natural opsins and offered a greater range of light sensitivity, making it potentially more useful for treating retinitis pigmentosa.

This type of noninvasive approach to optogenetics could also represent a step toward developing optogenetic treatments for diseases such as epilepsy, which could be controlled by shutting off misfiring neurons that cause seizures, Boyden says. "Since these molecules come from species other than humans, many studies must be done to evaluate their safety and efficacy in the context of treatment," he says.

Boyden's lab is working with many other research groups to further test the Jaws opsin for other applications. The team is also seeking new light-sensitive proteins and is working on high-throughput screening approaches that could speed up the development of such proteins.

The research at MIT was funded by Jerry and Marge Burnett, the Defense Advanced Research Projects Agency, the Human Frontiers Science Program, the IET A. F. Harvey Prize, the Janet and Sheldon Razin '59 Fellowship of the MIT McGovern Institute, the New York Stem Cell Foundation-Robertson Investigator Award, the National Institutes of Health, the National Science Foundation, and the Wallace H. Coulter Foundation.

---

Story Source:

The above story is based on materials provided by Massachusetts Institute of Technology. The original article was written by Anne Trafton. Note: Materials may be edited for content and length.

Read More